| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Pfizer Inc (ST: PFE)
PFE Technical Analysis
2
| As on 28th Feb 2023 PFE STOCK Price closed @ 422.60 and we RECOMMEND Sell for LONG-TERM with Stoploss of 471.03 & Strong Buy for SHORT-TERM with Stoploss of 376.64 we also expect STOCK to react on Following IMPORTANT LEVELS. |
PFESTOCK Price
| Open | 417.60 | Change | Price | % |
| High | 425.00 | 1 Day | -5.80 | -1.35 |
| Low | 417.40 | 1 Week | -28.20 | -6.26 |
| Close | 422.60 | 1 Month | -59.20 | -12.29 |
| Volume | 101044 | 1 Year | 37.30 | 9.68 |
| 52 Week High 565.00 | 52 Week Low 0.32 | ||||
ST Sweden Most Active Stocks
| FING-B | 0.04 | 0.00% |
| QLINEA | 0.50 | 284.62% |
| LIPI | 0.25 | -7.41% |
| SBB-B | 4.91 | 0.61% |
| LUNE | 21.97 | 6.65% |
| WYLD | 0.01 | 0.00% |
| KLAR | 0.61 | -8.96% |
| NIBE-B | 38.72 | -2.64% |
| EURA | 0.01 | 0.00% |
| BIM | 5.56 | 10.32% |
ST Sweden Top Gainers Stocks
ST Sweden Top Losers Stocks
| PFE Daily Charts |
PFE Intraday Charts |
Whats New @ Bazaartrend |
PFE Free Analysis |
|
|
PFE Important Levels Intraday
| RESISTANCE | 437.25 |
| RESISTANCE | 432.55 |
| RESISTANCE | 429.65 |
| RESISTANCE | 426.74 |
| SUPPORT | 418.46 |
| SUPPORT | 415.55 |
| SUPPORT | 412.65 |
| SUPPORT | 407.95 |
PFE Forecast January 2025
| 4th UP Forecast | 622.53 |
| 3rd UP Forecast | 558.41 |
| 2nd UP Forecast | 518.78 |
| 1st UP Forecast | 479.14 |
| 1st DOWN Forecast | 366.06 |
| 2nd DOWN Forecast | 326.42 |
| 3rd DOWN Forecast | 286.79 |
| 4th DOWN Forecast | 222.67 |
PFE Weekly Forecast
| 4th UP Forecast | 1096.61 |
| 3rd UP Forecast | 880.45 |
| 2nd UP Forecast | 746.84 |
| 1st UP Forecast | 613.22 |
| 1st DOWN Forecast | 231.98 |
| 2nd DOWN Forecast | 98.36 |
| 3rd DOWN Forecast | -35.25 |
| 4th DOWN Forecast | -251.41 |
PFE Forecast2025
| 4th UP Forecast | 1522.32 |
| 3rd UP Forecast | 1169.63 |
| 2nd UP Forecast | 951.63 |
| 1st UP Forecast | 733.63 |
| 1st DOWN Forecast | 111.57 |
| 2nd DOWN Forecast | -106.43 |
| 3rd DOWN Forecast | -324.43 |
| 4th DOWN Forecast | -677.12 |
Pfizer Inc ( ST Sweden Symbol : PFE )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
PFE Business Profile
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; Arvinas, Inc.; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Address: 235 East 42nd Street, New York, NY, United States, 10017
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service